Hypersomnia Clinical Trials, Drugs, Companies, Hypersomnia Treatment Market, 2025 | Avadel, Centessa Pharmaceuticals (UK) Limited, Takeda

Hypersomnia Pipeline constitutes 3+ key companies continuously working towards developing 4+ Hypersomnia treatment therapies, analyzes DelveInsight.
Hypersomnia Overview:

Hypersomnia is a disorder marked by excessive daytime sleepiness, which can greatly disrupt daily activities, productivity, and overall quality of life. It often results in sudden, unplanned episodes of sleep or drowsiness, known as sleep attacks, without obvious signs of tiredness beforehand. As a significant public health issue, hypersomnia is linked to increased risks of motor vehicle accidents and workplace injuries. Among its forms, Idiopathic Hypersomnia (IH) stands out as a rare, chronic condition characterized by an uncontrollable urge to sleep, prolonged and non-refreshing naps, and difficulty waking up, even after sufficient or extended nighttime sleep. First described by Bedrich Roth in 1956, IH is believed to have a neurological basis, though its exact underlying mechanisms are still not well understood, posing challenges for both diagnosis and treatment.

Request for a detailed insights report on Hypersomnia pipeline insights @ https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight [https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Hypersomnia Pipeline Insight 2025 [https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hypersomnia Therapeutics Market.

Key Takeaways from the Hypersomnia Pipeline Report

*
DelveInsight's Hypersomnia pipeline report depicts a robust space with 3+ active players working to develop 4+ pipeline therapies for Hypersomnia treatment.

*
YOLT-203 received Rare Pediatric Disease Designation in September 2024. This in vivo gene-editing therapy has initiated patient dosing, with a Phase 1 study expected to conclude by January 2026.

*
The FDA granted Rare Pediatric Disease Designation to META-001-PH in August 2024. Preclinical studies indicated up to an 80% reduction in urinary oxalate excretion. A Phase 1 trial is planned for early 2025.

*
In December 2024, the FDA approved a Phase 1/2 clinical trial for ABO-101, a gene-editing therapy targeting the HAO1 gene. This liver-directed treatment aims to provide a one-time solution by reducing oxalate production. The redePHine trial is expected to commence in the first half of 2025.

*
In October 2023, the FDA approved Rivfloza for patients aged 9 and older with PH1 and relatively preserved kidney function. This once-monthly subcutaneous RNAi therapy inhibits lactate dehydrogenase, a key enzyme in oxalate production. The approval was based on the PHYOX2 trial, which showed significant reductions in 24-hour urinary oxalate excretion.

*
Key Hypersomnia companies such as Avadel, Centessa Pharmaceuticals (UK) Limited, Takeda, and others are evaluating new drugs for Hypersomnia to improve the treatment landscape.

Hypersomnia Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Hypersomnia Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypersomnia treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypersomnia market.

Download our free sample page report on Hypersomnia pipeline insights @https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight [https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Hypersomnia Emerging Drugs

*
FT218: Avadel

FT218 (LUMRYZ) is an extended-release formulation of sodium oxybate developed to treat cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy. It functions as a central nervous system depressant, targeting gamma-aminobutyric acid (GABA) receptors to help regulate the sleep-wake cycle and alleviate narcolepsy symptoms. Unlike conventional twice-nightly oxybate therapies, LUMRYZ offers the convenience of a single, bedtime-only dose, improving patient compliance. The drug is currently in Phase III development for the treatment of hypersomnia.

*
ORX750: Centessa Pharmaceuticals (UK) Limited

ORX750 is an experimental, orally administered drug that acts as a highly potent and selective agonist of the orexin receptor 2 (OX2R), specifically developed to address the underlying cause of orexin neuron loss in narcolepsy type 1 (NT1). In laboratory studies, ORX750 demonstrated strong activation of OX2R with an in vitro EC50 of 0.11 nM and showed 9,800 times greater selectivity for OX2R over the human orexin receptor 1 (hOX1R). ORX750 is Centessa's first orexin-targeting candidate, currently under development for treating narcolepsy, with potential applications for narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other sleep-wake disorders. The drug is currently in Phase II clinical trials for hypersomnia treatment.

Hypersomnia Companies

There are around three or more major companies working on developing therapies for Hypersomnia. Among them, Avadel has a drug candidate currently in the most advanced stage, specifically Phase III of clinical development.

DelveInsight's report covers around 4+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Hypersomnia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Hypersomnia Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Hypersomnia Therapies and Key Companies: Hypersomnia Clinical Trials and advancements [https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Hypersomnia Pipeline Therapeutic Assessment

- Hypersomnia Assessment by Product Type

- Hypersomnia By Stage

- Hypersomnia Assessment by Route of Administration

- Hypersomnia Assessment by Molecule Type

Download Hypersomnia Sample report to know in detail about the Hypersomnia treatment market @ Hypersomnia Therapeutic Assessment [https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Hypersomnia Current Treatment Patterns

4. Hypersomnia - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Hypersomnia Late-Stage Products (Phase-III)

7. Hypersomnia Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hypersomnia Discontinued Products

13. Hypersomnia Product Profiles

14. Hypersomnia Key Companies

15. Hypersomnia Key Products

16. Dormant and Discontinued Products

17. Hypersomnia Unmet Needs

18. Hypersomnia Future Perspectives

19. Hypersomnia Analyst Review

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypersomnia-clinical-trials-drugs-companies-hypersomnia-treatment-market-2025-avadel-centessa-pharmaceuticals-uk-limited-takeda]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.